Sobre Nektar Therapeutics - Common Stock Visão geral da empresa da Wikipedia

Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.

Ler mais

Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.

Background

The company is engaged in developing a proprietary pipeline of drug candidates for several therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology. The company's research and development involve in small molecule and biologic drug candidates. Its drug candidate base consists of naloxegol (Movantik), a Phase III oral opioid antagonist, etirinotecan pegol, a topoisomerase inhibitor under Phase III clinical study as of 2012, NKTR 061, NKTR-181, NKTR-214, etc.

In 2013, the company was assigned a patent which was developed by the company and other four co-inventors. The products of the company is served as a supplement to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability and other areas of drugs for the patients worldwide. As of March 2014, the company had a market capitalization of $1.7 billion with an enterprise value of $1.67 billion.

As of December 2024, at a stock price-per-share of roughly $1, the market cap is roughly $171 million. Nektar underwent periods of downsizing after unsuccessful partnerships were ended with Eli Lilly in 2023 and Bristol Myers Squibb in 2022, resulting in layoffs of most company employees.

Pipeline

Etirinotecan pegol was in the phase III BEACON trial as well as in the I-SPY2 adaptive clinical trial for breast cancer in 2016. The European Medicines Agency refused a marketing authorisation in 2017.

Bempegaldesleukin (NKTR-214) is a CD122-biased immune-stimulatory cytokine, Phase I results were announced in November 2016. It is now in a phase 2 trial in combination with nivolumab for various advanced cancers.

In 2023 Nektar's partnership with Eli Lilly in development of "rezpeg" was ended. Eli Lilly claimed the drug lacked suitable efficacy, while Nektar responded that Eli Lilly had botched the analysis.

Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗

Wikidata ↗

NKTR Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas

Preço

$75.92

Capitalização de Mercado

$2.24B

P/E (TTM)

-11.3

EPS (TTM)

$-9.73

Receita (TTM)

$55M

Rendimento div.

—

ROE

-500.1%

Dívida/Capital

—

Intervalo 52 Semanas

$25 – $109

NKTR Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização

Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS

Receita e Lucro Líquido $55M

2016-12-31 → 2025-12-31

EPS $-9.73

2016-12-31 → 2025-12-31

Fluxo de caixa livre $-209M

2016-12-31 → 2025-12-31

Margens -297.1%

Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?

Métrica

Tendência de 5 anos

NKTR

Mediana de Pares

P/E (TTM)

-11.3

29.4

P/S (TTM)

40.5

4.9

P/B

24.9

6.5

Price / FCF (Preço / FCF)

-10.7

—

Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC

Métrica

Tendência de 5 anos

NKTR

Mediana de Pares

Operating Margin (Margem Operacional)

-253.7%

—

Net Profit Margin (Margem de Lucro Líquido)

-297.1%

-9.0%

ROA

-56.2%

-8.2%

ROE

-500.1%

-19.4%

ROIC

-155.8%

—

Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial

Métrica

Tendência de 5 anos

NKTR

Mediana de Pares

Current Ratio (Índice de liquidez corrente)

5.0

3.6

Quick Ratio (Índice de Liquidez Seca)

0.3

—

Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos

Métrica

Tendência de 5 anos

NKTR

Mediana de Pares

Revenue YoY (Receita Ano a Ano)

-43.9%

—

Revenue CAGR 3Y (CAGR Receita 3A)

-15.7%

—

Revenue CAGR 5Y (CAGR Receita 5A)

-18.4%

—

Métricas por Ação EPS, valor patrimonial por ação, fluxo de caixa por ação, dividendo por ação

Métrica

Tendência de 5 anos

NKTR

Mediana de Pares

EPS (Diluted) (EPS (Diluído))

$-9.73

—

Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber

Métrica

Tendência de 5 anos

NKTR

Mediana de Pares

NKTR Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta

COMPRA 17 analistas

Compra forte 7 41,2%
Compra 8 47,1%
Manter 2 11,8%
Venda 0 0,0%
Venda forte 0 0,0%

Preço-alvo de 12 meses

9 analistas · 2026-08-16

Mediana $151.00

← Abaixo de todos os alvos $75.92

Mín $80.00

Máx $192.00

Alvo mediano $151.00 +98,9%

Alvo médio $153.22 +101,8%

Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados

Surpresa Média

0.21%

Período	EPS Actual	EPS est.	Surpresa
30 de Junho de 2026	$-1.23	$-2.02	0.79%
31 de Março de 2026	$-1.82	$-1.63	-0.19%
31 de Dezembro de 2025	$-1.78	$-2.52	0.74%
30 de Setembro de 2025	$-1.87	$-2.74	0.87%
30 de Junho de 2025	$-2.95	$-3.10	0.15%
31 de Março de 2025	$-3.60	$-2.51	-1.1%

Comparação de pares (subindústria GICS) Métricas chave vs pares do setor

Ticker	Capitalização de Mercado	P/E	Receita YoY	Margem Líquida	ROE	Margem Bruta
NKTR	$862M	-4.3	-43.9%	-297.1%	-500.1%	—
ALMS	—	-3.4	—	-1011.8%	-61.9%	—
TARS	$3.48B	-51.5	146.7%	-14.7%	-19.7%	—
SUPN	$2.86B	-73.1	8.6%	-5.4%	-3.6%	—
ATAI	$223M	-1.4	-1.9%	-48464.0%	-83.1%	—
TRVI	$1.61B	-39.1	—	—	-22.4%	—
AMRX	—	57.3	8.1%	2.4%	-80.0%	36.9%
AMLX	$1.33B	-7.9	-77.1%	—	-61.2%	—
PBH	$3.33B	15.2	-4.3%	17.5%	10.2%	54.7%
RAPP	$1.45B	-10.6	—	—	-29.8%	—
OCUL	$2.62B	-8.5	-18.5%	-511.9%	-55.4%	—

Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa

Demonstração de Resultados 17

Dados anuais de Demonstração de Resultados para NKTR
Métrica	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	$55M	$98M	$90M	$92M	$102M	$153M	$115M	$1.19B	$308M	$165M	$231M	$201M
Cost of Revenue	$0	$31M	$34M	$22M	$25M	$19M	$21M	$24M	$31M	$30M	$34M	$29M
R&D Expense	$117M	$121M	$114M	$218M	$400M	$409M	$435M	$400M	$268M	$204M	$183M	$148M
SG&A Expense	$69M	$77M	$77M	$92M	$123M	$105M	$99M	$81M	$52M	$44M	$43M	$41M
Operating Expenses	$195M	$204M	$354M	$468M	$548M	$578M	$555M	$505M	$367M	$278M	$260M	$217M
Operating Income	$-140M	$-105M	$-264M	$-376M	$-446M	$-425M	$-440M	$688M	$-60M	$-113M	$-29M	$-16M
Interest Expense	·	·	·	$0	$0	$7M	$21M	$22M	$22M	$22M	$18M	$18M
Interest Income	$10M	$14M	$19M	$7M	$3M	·	·	·	·	·	·	·
Other Non-op	$361.0K	$-390.0K	$-6M	$-116.0K	$-162.0K	$18M	$46M	$38M	$5M	$2M	$2M	$814.0K
Pretax Income	$-164M	$-119M	$-276M	$-365M	$-523M	$-444M	$-440M	$683M	$-96M	$-153M	$-81M	$-54M
Income Tax	$-138.0K	$-239.0K	$-200.0K	$3M	$557.0K	$493.0K	$613.0K	$1M	$616.0K	$876.0K	$506.0K	$-512.0K
Net Income	$-164M	$-119M	$-276M	$-368M	$-524M	$-444M	$-441M	$681M	$-97M	$-154M	$-81M	$-54M
EPS (Basic)	$-9.73	$-8.68	$-1.45	$-1.97	$-2.86	$-2.49	$-2.52	$4.02	$-0.62	$-1.10	·	·
EPS (Diluted)	$-9.73	$-8.68	$-1.45	$-1.97	$-2.86	$-2.49	$-2.52	$3.78	$-0.62	$-1.10	·	·
Shares (Basic)	16,870,930	13,710,775	190,001,000	187,138,000	183,298,000	178,581,000	174,993,000	169,600,000	155,953,000	139,596,000	·	·
Shares (Diluted)	16,870,930	13,710,775	190,001,000	187,138,000	183,298,000	178,581,000	174,993,000	180,119,000	155,953,000	139,596,000	·	·
EBITDA	$-140M	$-101M	$-257M	$-364M	$-433M	$-413M	$-429M	$697M	$-47M	$-113M	$-29M	·

Balanço Patrimonial 24

Dados anuais de Balanço Patrimonial para NKTR
Métrica	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Cash & Equivalents	$15M	$44M	$35M	$88M	$25M	$199M	$96M	$195M	$5M	$60M	$56M	$12M
Short-term Investments	·	·	·	·	·	·	·	·	$291M	$329M	$253M	$225M
Receivables	·	$0	$1M	$6M	$22M	$39M	$37M	$43M	$5M	$16M	$20M	$4M
Inventory	$0	$0	$16M	$19M	$16M	$15M	$13M	$11M	$11M	$11M	$11M	$13M
Other Current Assets	$21M	$6M	$10M	$16M	$23M	$22M	$15M	$21M	$8M	$10M	$10M	$9M
Current Assets	$266M	$261M	$331M	$546M	$796M	$1.14B	$1.42B	$1.44B	$327M	$426M	$350M	$288M
PP&E (Net)	$2M	$3M	$19M	$32M	$61M	$60M	$66M	$49M	$47M	$66M	$71M	$70M
Accum. Depreciation	·	$16M	$87M	$125M	$148M	$138M	$128M	$121M	$115M	$111M	$103M	$94M
Goodwill	·	·	$0	$77M	$77M	$77M	$77M	$77M	$77M	$77M	$77M	$77M
Other Non-current Assets	$14M	$5M	$5M	$2M	$3M	$1M	$344.0K	$4M	$994.0K	$817.0K	$754.0K	$7M
Total Assets	$280M	$304M	$398M	$711M	$1.12B	$1.54B	$1.98B	$2.15B	$509M	$569M	$499M	$442M
Accounts Payable	$11M	$12M	$10M	$13M	$10M	$22M	$19M	$6M	$5M	$3M	$2M	$3M
Accrued Liabilities	$22M	$30M	$22M	$37M	·	·	·	·	·	·	·	$6M
Current Liabilities	$54M	$61M	$51M	$68M	$85M	$116M	$354M	$82M	$56M	$72M	$61M	$64M
Capital Leases	$65M	$83M	$99M	$113M	$126M	$136M	$143M	$0	·	$2M	$1M	$4M
Other Non-current Liabilities	$9M	$7M	$5M	$8M	$4M	$9M	$768.0K	$10M	$6M	$7M	$10M	$15M
Total Liabilities	$191M	$243M	$267M	$344M	$438M	$461M	$572M	$433M	$421M	$481M	$492M	$405M
Common Stock	$2.0K	$1.0K	$19.0K	$19.0K	$19.0K	$18.0K	$17.0K	$17.0K	$15.0K	$15.0K	$13.0K	$13.0K
Retained Earnings	$-3.76B	$-3.60B	$-3.48B	$-3.20B	$-2.83B	$-2.31B	$-1.86B	$-1.42B	$-2.12B	$-2.02B	$-1.87B	$-1.79B
Treasury Stock	·	$3M	$0	·	·	·	·	·	·	·	·	·
AOCI	$17.0K	$61.0K	$80.0K	$-7M	$-4M	$-2M	$-1M	$-6M	$-2M	$-2M	$-2M	$-2M
Stockholders' Equity	$90M	$61M	$131M	$367M	$680M	$1.08B	$1.41B	$1.72B	$88M	$88M	$6M	$36M
Liabilities + Equity	$280M	$304M	$398M	$711M	$1.12B	$1.54B	$1.98B	$2.15B	$509M	$569M	$499M	$442M
Shares Outstanding	20,378,832	12,385,001	12,757,984	188,560,000	185,468,000	180,091,000	176,505,000	173,530,000	159,524,000	153,212,000	135,289,000	131,216,000

Fluxo de Caixa 14

Dados anuais de Fluxo de Caixa para NKTR
Métrica	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
D&A	$1M	$4M	$7M	$12M	$13M	$12M	$11M	$9M	$13M	$13M	$11M	$13M
Stock-based Comp	·	·	·	·	·	·	·	·	·	·	·	$17M
Deferred Tax	$64.0K	$-10.0K	$-140.0K	$3M	$-102.0K	$-36.0K	$-21.0K	$93.0K	$35.0K	$-115.0K	$-22.0K	$-31.0K
Other Non-cash	·	$-61M	$77M	$49M	$98M	$119M	$101M	$28M	$4M	·	·	·
Operating Cash Flow	$-209M	$-176M	$-193M	$-304M	$-413M	$-313M	$-329M	$718M	$-80M	$-117M	$-73M	$-142M
CapEx	$171.0K	$1M	$865.0K	$6M	$15M	$7M	$26M	$14M	$10M	$6M	$11M	$10M
Investing Cash Flow	$-1M	$143M	$140M	$366M	$203M	$496M	$207M	$-1.38B	$-29M	$-82M	·	·
Stock Repurchased	$0	$3M	$0	·	·	·	·	·	·	·	·	·
Net Stock Activity	$0	$-3M	·	·	·	·	·	·	·	·	·	·
Financing Cash Flow	$181M	$42M	$30.0K	$2M	$36M	$-80M	$23M	$852M	$54M	$204M	·	·
Net Change in Cash	$-29M	$9M	$-53M	$63M	$-174M	$103M	$-99M	$190M	$-55M	$4M	$43M	$-27M
Taxes Paid	$-195.0K	$76.0K	$3M	$272.0K	$325.0K	$539.0K	$555.0K	$618.0K	$556.0K	$757.0K	$860.0K	$964.0K
Free Cash Flow	$-209M	$-177M	$-193M	$-310M	$-428M	$-321M	$-355M	$704M	$-90M	$-123M	$-84M	·
Levered FCF	·	·	·	$-310M	$-428M	$-327M	$-376M	$682M	$-112M	$-146M	$-103M	·

Lucratividade 7

Dados anuais de Lucratividade para NKTR
Métrica	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Operating Margin	-253.7%	-106.9%	-292.6%	-408.6%	-437.8%	-278.0%	-383.9%	57.6%	-19.4%	-68.2%	-12.7%	·
Net Margin	-297.1%	-120.9%	-306.3%	-400.0%	-514.0%	-290.6%	-384.5%	57.1%	-31.4%	-92.8%	-35.2%	·
Pretax Margin	-297.3%	-121.1%	-306.5%	-396.5%	-513.5%	-290.3%	-383.9%	57.2%	-31.2%	-92.3%	-35.0%	·
EBITDA Margin	-253.7%	-102.7%	-284.8%	-395.4%	-425.0%	-269.8%	-374.3%	58.4%	-15.3%	-68.2%	-12.7%	·
ROA	-56.2%	-33.9%	-49.8%	-40.3%	-39.5%	-25.3%	-21.3%	51.2%	-17.9%	-28.8%	-17.2%	·
ROE	-500.1%	-217.0%	-190.2%	-94.5%	-70.7%	-39.5%	-30.4%	38.9%	-109.9%	-324.7%	-379.7%	·
ROIC	-155.8%	-172.9%	-201.2%	-103.5%	-65.7%	-39.5%	-31.4%	40.0%	-68.3%	-128.8%	-459.7%	·

Liquidez e Solvência 3

Dados anuais de Liquidez e Solvência para NKTR
Métrica	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Current Ratio	5.0	4.3	6.5	8.0	9.3	9.8	4.0	17.5	5.8	5.9	5.7	·
Quick Ratio	0.3	0.7	0.7	1.4	0.6	2.1	0.4	2.9	5.4	5.6	5.4	·
Interest Coverage	·	·	·	·	·	-62.1	-20.6	31.9	-2.7	-5.0	-1.6	·

Eficiência 3

Dados anuais de Eficiência para NKTR
Métrica	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Asset Turnover	0.2	0.3	0.2	0.1	0.1	0.1	0.1	0.9	0.6	0.3	0.5	·
Inventory Turnover	·	3.8	1.9	1.2	1.6	1.4	1.8	2.2	2.8	2.7	2.8	·
Receivables Turnover	·	163.4	25.1	6.5	3.3	4.0	2.9	49.5	29.7	9.3	19.6	·

Por Ação 5

Dados anuais de Por Ação para NKTR
Métrica	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Book Value / Share	$4.41	$0.33	$0.68	$1.94	$3.66	$5.98	$7.96	$9.90	$0.55	$0.58	$0.05	·
Revenue / Share	$3.27	$0.48	$0.47	$0.49	$0.56	$0.86	$0.66	$6.63	·	·	·	·
Cash Flow / Share	$-12.36	$-0.85	$-1.01	$-1.62	$-2.25	$-1.75	$-1.88	$3.99	·	·	·	·
Cash / Share	$0.74	$0.24	$0.18	$0.47	$0.14	$1.10	$0.55	$1.12	$0.03	$0.39	$0.41	·
EPS (TTM)	$-9.73	$-8.68	$-1.45	$-1.97	$-2.86	$-2.49	$-2.52	$3.78	$-0.62	$-1.10	$-0.61	$-0.45

Taxas de Crescimento 3

Dados anuais de Taxas de Crescimento para NKTR
Métrica	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue YoY	-43.9%	9.2%	-2.1%	-9.7%	-33.4%	·	·	·	·	·	·	·
Revenue CAGR 3Y	-15.7%	-1.1%	-16.2%	·	·	·	·	·	·	·	·	·
Revenue CAGR 5Y	-18.4%	·	·	·	·	·	·	·	·	·	·	·

Avaliação (TTM) 10

Dados anuais de Avaliação (TTM) para NKTR
Métrica	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue TTM	$55M	$98M	$90M	$92M	$102M	$153M	$115M	$1.19B	$308M	$165M	$231M	$201M
Net Income TTM	$-164M	$-119M	$-276M	$-368M	$-524M	$-444M	$-441M	$681M	$-97M	$-154M	$-81M	$-54M
Market Cap	$862M	$2.59B	$1.61B	$6.39B	$37.59B	$45.92B	$57.16B	$85.56B	$142.90B	$28.20B	$34.19B	·
P/E	-4.3	-1.6	-5.8	-17.2	-70.9	-102.4	-128.5	130.4	-1444.8	-167.3	-414.3	-516.7
P/S	15.6	26.3	17.8	69.4	368.8	300.3	498.7	71.7	464.4	170.5	148.2	·
P/B	9.6	42.7	12.3	17.4	55.3	42.6	40.7	49.8	1627.1	320.0	5318.8	·
P / Tangible Book	9.6	42.7	12.3	22.0	62.3	45.9	·	·	·	·	·	·
P / Cash Flow	-4.1	-14.7	-8.3	-21.0	-91.1	-146.6	-173.9	119.1	-1777.1	-241.0	-467.9	·
P / FCF	-4.1	-14.6	-8.3	-20.6	-87.9	-143.3	-161.0	121.5	-1586.2	-228.5	-405.7	·
Earnings Yield	-23.0%	-62.2%	-17.3%	-5.8%	-1.4%	-0.98%	-0.78%	0.77%	-0.07%	-0.60%	-0.24%	-0.19%

Demonstração de Resultados 16

Dados trimestrais de Demonstração de Resultados para NKTR
Métrica	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Revenue	$10M	$11M	$22M	$12M	$11M	$10M	$29M	$24M	$23M	$22M	$24M	$24M	$20M	$22M	$22M	$24M
Cost of Revenue	·	·	$0	$0	$0	$0	$8M	$4M	$10M	$9M	$7M	$12M	$7M	$7M	$6M	$5M
R&D Expense	$39M	$36M	$30M	$27M	$30M	$30M	$29M	$35M	$30M	$27M	$30M	$24M	$30M	$30M	$35M	$34M
SG&A Expense	$13M	$13M	$11M	$16M	$17M	$24M	$17M	$19M	$21M	$20M	$17M	$21M	$18M	$21M	$22M	$23M
Operating Expenses	$52M	$50M	$49M	$43M	$47M	$55M	$15M	$58M	$73M	$57M	$57M	$69M	$71M	$156M	$74M	$78M
Operating Income	$-42M	$-39M	$-28M	$-32M	$-36M	$-45M	$14M	$-34M	$-50M	$-35M	$-34M	$-45M	$-51M	$-135M	$-52M	$-54M
Interest Income	$9M	$4M	$3M	$3M	$2M	$3M	$3M	$3M	$4M	$4M	$5M	$5M	$5M	$4M	·	·
Other Non-op	$-100.0K	$-336.0K	$-44.0K	$-121.0K	$260.0K	$266.0K	$-135.0K	$-120.0K	$-36.0K	$-99.0K	$-6M	$-335.0K	$736.0K	$-301.0K	$-4M	$2M
Pretax Income	$-40M	$-43M	$-43M	$-35M	$-39M	$-46M	$7M	$-37M	$-52M	$-37M	$-42M	$-46M	$-51M	$-137M	$-57M	$-59M
Income Tax	$2.0K	$64.0K	$31.0K	$-33.0K	$-188.0K	$52.0K	$-259.0K	$9.0K	$46.0K	$-35.0K	$-29.0K	$-61.0K	$-47.0K	$-63.0K	$3M	$-155.0K
Net Income	$-41M	$-45M	$-36M	$-36M	$-42M	$-51M	$7M	$-37M	$-52M	$-37M	$-42M	$-46M	$-51M	$-137M	$-60M	$-59M
EPS (Basic)	$-1.23	$-1.82	$-4.67	$-1.87	$-2.95	$-3.62	$-2.07	$-2.66	$-3.76	$-0.19	$-0.21	$-0.24	$-0.27	$-0.73	$-0.32	$-0.31
EPS (Diluted)	$-1.23	$-1.82	$-4.67	$-1.87	$-2.95	$-3.62	$-2.07	$-2.66	$-3.76	$-0.19	$-0.21	$-0.24	$-0.27	$-0.73	$-0.32	$-0.31
Shares (Basic)	33,054,865	24,736,066	-227,086,936	18,946,559	14,087,307	14,063,402	-208,906,454	13,949,851	13,921,378	194,746,000	-378,936,000	190,406,000	189,656,000	188,875,000	-373,151,000	187,641,000
Shares (Diluted)	33,054,865	24,736,066	-227,086,936	18,946,559	14,087,307	14,063,402	-208,906,454	13,949,851	13,921,378	194,746,000	-378,936,000	190,406,000	189,656,000	188,875,000	-373,151,000	187,641,000
EBITDA	$-42M	$-39M	·	$-32M	$-36M	$-45M	·	$-34M	$-50M	$-35M	·	$-45M	$-51M	$-135M	·	$-54M

Balanço Patrimonial 23

Dados trimestrais de Balanço Patrimonial para NKTR
Métrica	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Cash & Equivalents	$39M	$150M	$15M	$41M	$43M	$39M	$44M	$30M	$28M	$49M	$35M	$65M	$51M	$77M	$88M	$106M
Receivables	·	·	·	·	·	·	·	$0	$1M	$4M	$1M	$2M	$1M	$3M	$6M	$12M
Inventory	·	·	$0	·	·	·	$0	$0	$14M	$16M	$16M	$15M	$21M	$20M	$19M	$19M
Other Current Assets	$55M	$20M	$21M	$11M	$11M	$11M	$6M	$9M	$8M	$11M	$10M	$9M	$10M	$11M	$16M	$23M
Current Assets	$739M	$589M	$266M	$281M	$187M	$230M	$261M	$286M	$295M	$320M	$331M	$399M	$441M	$491M	$546M	$599M
PP&E (Net)	·	·	$2M	$3M	$3M	$3M	$3M	$4M	$15M	$17M	$19M	$20M	$23M	$27M	$32M	$37M
Accum. Depreciation	·	·	·	·	·	·	·	$16M	$88M	·	$87M	$88M	$108M	$111M	$125M	·
Goodwill	·	·	·	·	·	·	·	·	·	·	$0	$0	$0	$0	$77M	$77M
Other Non-current Assets	$17M	$11M	$6M	$5M	$5M	$5M	$5M	$5M	$4M	$5M	$5M	$5M	$2M	$1M	$2M	$2M
Total Assets	$1.10B	$763M	$280M	$301M	$208M	$256M	$304M	$308M	$343M	$396M	$398M	$442M	$494M	$562M	$711M	$781M
Accounts Payable	$25M	$10M	$11M	$16M	$14M	$18M	$12M	$9M	$6M	$9M	$10M	$3M	$3M	$4M	$13M	$5M
Accrued Liabilities	$23M	$25M	$22M	$29M	$35M	$31M	$30M	$32M	$30M	$24M	$22M	$30M	$29M	$37M	$37M	·
Current Liabilities	$71M	$58M	$54M	$66M	$71M	$71M	$61M	$68M	$57M	$52M	$51M	$52M	$51M	$60M	$68M	$84M
Capital Leases	$56M	$61M	$65M	$70M	$74M	$78M	$83M	$87M	$91M	$95M	$99M	$102M	$106M	$109M	$113M	$116M
Other Non-current Liabilities	$8M	$8M	$9M	$5M	$6M	$7M	$7M	$7M	$8M	$4M	$5M	$5M	$5M	$6M	$8M	$3M
Total Liabilities	$192M	$187M	$191M	$216M	$232M	$243M	$243M	$259M	$264M	$269M	$267M	$283M	$297M	$321M	$344M	$369M
Common Stock	$3.0K	$3.0K	$2.0K	$2.0K	$1.0K	$19.0K	$1.0K	$19.0K	$19.0K	$19.0K	$19.0K	$19.0K	$19.0K	$19.0K	$19.0K	$19.0K
Retained Earnings	$-3.85B	$-3.81B	$-3.76B	$-3.72B	$-3.69B	$-3.65B	$-3.60B	$-3.60B	$-3.57B	$-3.51B	$-3.48B	$-3.44B	$-3.39B	$-3.34B	$-3.20B	$-3.14B
Treasury Stock	·	·	·	$0	$3M	$3M	$3M	$3M	$3M	$3M	·	·	·	·	·	·
AOCI	$-2M	$-1M	$17.0K	$56.0K	$-14.0K	$39.0K	$61.0K	$355.0K	$-494.0K	$-403.0K	$80.0K	$-6M	$-6M	$-6M	$-7M	$-8M
Stockholders' Equity	$903M	$576M	$90M	$85M	$-24M	$14M	$61M	$49M	$80M	$127M	$131M	$159M	$197M	$241M	$367M	$412M
Liabilities + Equity	$1.10B	$763M	$280M	$301M	$208M	$256M	$304M	$308M	$343M	$396M	$398M	$442M	$494M	$562M	$711M	$781M
Shares Outstanding	20,378,832	20,378,832	20,378,832	19,652,513	12,457,252	186,103,000	12,385,001	184,458,000	184,061,000	183,624,000	191,384,000	190,771,000	190,119,000	189,235,000	188,560,000	187,954,000

Fluxo de Caixa 12

Dados trimestrais de Fluxo de Caixa para NKTR
Métrica	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
D&A	$156.0K	$151.0K	$190.0K	$196.0K	$214.0K	$426.0K	$332.0K	$993.0K	$1M	$2M	$2M	$2M	$2M	$2M	$3M	$3M
Deferred Tax	·	·	·	·	·	·	$2.0K	$-31.0K	$57.0K	$-38.0K	$2M	$-15.0K	$-27.0K	$-2M	$3M	$0
Restructuring	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	$17M
Operating Cash Flow	$-76M	$-44M	$-65M	$-49M	$-46M	$-49M	$-46M	$-44M	$-38M	$-48M	$-47M	$-42M	$-52M	$-52M	$-58M	$-83M
CapEx	$94.0K	$18.0K	$18.0K	$114.0K	$37.0K	$2.0K	$459.0K	$666.0K	$186.0K	$157.0K	$237.0K	$33.0K	$162.0K	$433.0K	$512.0K	$181.0K
Investing Cash Flow	$-399M	$-351M	$372.0K	$-95M	$50M	$44M	$60M	$46M	$17M	$19M	$17M	$56M	$25M	$41M	$40M	$111M
Stock Repurchased	·	·	$0	$0	$0	$0	$0	$0	$0	$3M	$0	$0	$0	$0	·	·
Net Stock Activity	·	·	·	·	·	$0	·	·	·	$-3M	·	·	·	·	·	·
Financing Cash Flow	$365M	$530M	$39M	$142M	$211.0K	$7.0K	$83.0K	$13.0K	$19.0K	$42M	$12.0K	$0	$18.0K	$0	$103.0K	$0
Net Change in Cash	$-110M	$134M	$-26M	$-2M	$4M	$-5M	$14M	$2M	$-21M	$13M	$-30M	$14M	$-26M	$-11M	$-18M	$28M
Taxes Paid	·	·	·	·	·	·	·	·	·	·	$0	$0	·	·	$272.0K	$-85.0K
Free Cash Flow	·	$-44M	·	·	·	$-49M	·	·	·	$-48M	·	·	·	$-52M	·	·

Lucratividade 7

Dados trimestrais de Lucratividade para NKTR
Métrica	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Operating Margin	-417.9%	-359.6%	·	-268.6%	-324.2%	-425.8%	·	-142.4%	-211.9%	-163.7%	·	-185.8%	-246.8%	-623.8%	·	-229.9%
Net Margin	-401.0%	-413.4%	·	-301.3%	-372.2%	-486.4%	·	-153.6%	-222.9%	-170.1%	·	-189.8%	-249.4%	-634.5%	·	-249.9%
Pretax Margin	-397.8%	-396.7%	·	-297.0%	-352.5%	-443.3%	·	-153.6%	-222.7%	-170.2%	·	-190.1%	-249.6%	-634.8%	·	-250.6%
EBITDA Margin	-417.9%	-359.6%	·	-268.6%	-324.2%	-425.8%	·	-142.4%	-211.9%	-163.7%	·	-185.8%	-246.8%	-623.8%	·	-229.9%
ROA	-6.2%	-8.8%	·	-11.7%	-15.1%	-15.6%	·	-9.9%	-12.5%	-7.7%	·	-7.5%	-7.5%	-17.3%	·	-5.7%
ROE	-9.2%	-15.2%	·	-53.0%	-150.0%	-72.5%	·	-35.6%	-37.9%	-20.0%	·	-16.0%	-15.6%	-32.3%	·	-9.7%
ROIC	-4.7%	-6.8%	·	-37.2%	148.9%	-324.5%	·	-70.3%	-62.5%	-27.9%	·	-28.1%	-25.7%	-55.9%	·	-13.1%

Liquidez e Solvência 2

Dados trimestrais de Liquidez e Solvência para NKTR
Métrica	Tendência	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Current Ratio		10.4	10.2	·	4.2	2.6	3.2	·	4.2	5.1	6.1	·	7.7	8.7	8.2	·	7.1
Quick Ratio		0.6	2.6	·	0.6	0.6	0.5	·	0.4	0.5	1.0	·	1.3	1.0	1.3	·	1.4

Eficiência 3

Dados trimestrais de Eficiência para NKTR
Métrica	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Asset Turnover	0.0	0.0	·	0.0	0.0	0.0	·	0.1	0.1	0.0	·	0.0	0.0	0.0	·	0.0
Inventory Turnover	·	·	·	·	·	·	·	0.6	0.6	0.5	·	0.7	0.4	0.4	·	0.3
Receivables Turnover	·	·	·	·	·	·	·	21.9	18.6	6.5	·	3.5	3.6	1.3	·	1.2

Por Ação 5

Dados trimestrais de Por Ação para NKTR
Métrica	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Book Value / Share	$44.32	$28.28	·	$4.33	$-1.94	$0.07	·	$0.27	$0.43	$0.69	·	$0.84	$1.04	$1.27	·	$2.19
Revenue / Share	$0.31	$0.44	·	$0.62	$0.79	$0.05	·	$0.12	$0.11	$0.11	·	$0.13	$0.11	$0.11	·	$0.13
Cash Flow / Share	·	$-1.79	·	·	·	$-0.23	·	·	·	$-0.25	·	·	·	$-0.27	·	·
Cash / Share	$1.93	$7.34	·	$2.09	$3.45	$0.21	·	$0.16	$0.15	$0.26	·	$0.34	$0.27	$0.41	·	$0.56
EPS (TTM)	$-7.87	$-10.26	·	$-7.72	$-9.61	$-6.85	·	$-6.85	$-4.46	$-1.43	·	$-1.55	$-2.16	$-2.38	·	$-791.65

Avaliação (TTM) 10

Dados trimestrais de Avaliação (TTM) para NKTR
Métrica	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Revenue TTM	$44M	$44M	·	$58M	$69M	$80M	·	$93M	$90M	$88M	·	$90M	$87M	$92M	·	$95M
Net Income TTM	$-163M	$-173M	·	$-165M	$-182M	$-177M	·	$-172M	$-186M	$-271M	·	$-293M	$-406M	$-446M	·	$-454M
Market Cap	$1.42B	$1.47B	·	$1.12B	$322M	$1.90B	·	$3.60B	$3.42B	$2.56B	·	$1.72B	$1.65B	$1.99B	·	$9.02B
P/E	-8.9	-7.0	·	-7.4	-2.7	-1.5	·	-2.8	-4.2	-9.8	·	-5.8	-4.0	-4.4	·	-0.1
P/S	32.4	33.1	·	19.4	4.6	23.8	·	38.5	38.1	29.1	·	19.1	18.9	21.7	·	94.9
P/B	1.6	2.5	·	13.1	-13.3	138.2	·	73.6	43.0	20.2	·	10.8	8.4	8.2	·	21.9
P / Tangible Book	1.6	2.5	·	13.1	·	138.2	·	73.6	43.0	20.2	·	10.8	8.4	8.2	·	26.9
P / Cash Flow	·	-33.1	·	·	·	-38.7	·	·	·	-53.5	·	·	·	-38.3	·	·
P / FCF	·	-33.1	·	·	·	-38.7	·	·	·	-53.3	·	·	·	-38.0	·	·
Earnings Yield	-11.3%	-14.3%	·	-13.6%	-37.2%	-67.2%	·	-35.1%	-24.0%	-10.2%	·	-17.2%	-24.8%	-22.7%	·	-1649.3%

Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos

Demonstração de Resultados

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Receita	$55M	$98M	$90M	$92M	$102M
Margem Operacional %	-253.7%	-106.9%	-292.6%	-408.6%	-437.8%
Lucro líquido	$-164M	$-119M	$-276M	$-368M	$-524M
EPS Diluído	$-9.73	$-8.68	$-1.45	$-1.97	$-2.86

Balanço Patrimonial

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Índice de liquidez corrente	5.0	4.3	6.5	8.0	9.3
Índice de Liquidez Seca	0.3	0.7	0.7	1.4	0.6

Fluxo de Caixa

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Fluxo de caixa livre	$-209M	$-177M	$-193M	$-310M	$-428M

Últimas notícias Notícias recentes mencionando esta empresa

Patient Square Faz Grande Aposta na Nektar Pharmaceuticals (NKTR) Comprando 210.000 Ações Nasdaq · 3 meses atrás

Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos

📊

Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.

Sua seleção é salva e acompanha você em todos os tickers.

Investidores institucionais (13F) 269 declarantes · $2.1B total · Em 30 de Junho de 2026

Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.

Atividade institucional — Q2 2026 vs trimestre anterior

Novas posições	Posições encerradas	Aumentou	Diminuído	Variação líquida de ações
88 (+20 vs trimestre anterior)	41 (+9 vs trimestre anterior)	91 (+21 vs trimestre anterior)	48 (-8 vs trimestre anterior)	+8.5M

Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.

Instituição	Valor	Ações	% de 13F rastreado	Tipo
Two Seas Capital LP	$215.868.856	3.092.234	10,35%	Ações
FMR LLC	$192.088.149	2.751.585	9,21%	Ações
BVF INC/IL	$166.920.946	2.391.075	8,00%	Ações
VANGUARD CAPITAL MANAGEMENT LLC	$104.495.029	1.496.849	5,01%	Ações
TWO SIGMA INVESTMENTS, LP	$83.911.899	1.202.004	4,02%	Ações
Vestal Point Capital, LP	$69.810.000	1.000.000	3,35%	Ações
STATE STREET CORP	$63.504.691	909.679	3,04%	Ações
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$57.502.497	823.700	2,76%	Opção de compra
Prosight Management, LP	$56.546.100	810.000	2,71%	Ações
GEODE CAPITAL MANAGEMENT, LLC	$52.759.799	755.586	2,53%	Ações
ARMISTICE CAPITAL, LLC	$50.542.440	724.000	2,42%	Ações
GILDER GAGNON HOWE & CO LLC	$41.946.944	600.873	2,01%	Ações
MILLENNIUM MANAGEMENT LLC	$33.377.557	478.120	1,60%	Ações
BRAIDWELL LP	$33.063.203	473.617	1,59%	Ações
Sofinnova Investments, Inc.	$32.933.775	471.763	1,58%	Ações
Woodline Partners LP	$32.871.784	470.875	1,58%	Ações
ORBIMED ADVISORS LLC	$32.485.804	465.346	1,56%	Ações
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$27.540.045	394.500	1,32%	Opção de venda
EMERALD ADVISERS, LLC	$27.236.930	390.158	1,31%	Ações
VANGUARD PORTFOLIO MANAGEMENT LLC	$24.331.577	348.540	1,17%	Ações
DAFNA Capital Management LLC	$22.226.108	318.380	1,07%	Ações
Deep Track Capital, LP	$20.943.000	300.000	1,00%	Ações
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	$19.893.826	284.971	0,95%	Ações
22NW, LP	$19.624.638	281.115	0,94%	Ações
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$19.475.384	278.977	0,93%	Ações
PRIMECAP MANAGEMENT CO/CA/	$19.047.658	272.850	0,91%	Ações
Nearwater Capital Markets, Ltd	$18.255.315	261.500	0,88%	Ações
BARCLAYS PLC	$17.968.815	257.396	0,86%	Ações
EMERALD MUTUAL FUND ADVISERS TRUST	$17.842.528	255.587	0,86%	Ações
ADAR1 Capital Management, LLC	$17.046.485	244.184	0,82%	Ações
Creek Drive Management Group LLC	$16.963.830	243.000	0,81%	Ações
SEVEN GRAND MANAGERS, LLC	$16.754.400	240.000	0,80%	Ações
VANGUARD FIDUCIARY TRUST CO	$16.724.731	239.575	0,80%	Ações
NORGES BANK	$15.030.093	215.300	0,72%	Ações
Bronte Capital Management Pty Ltd.	$13.852.678	198.434	0,66%	Ações
TWO SIGMA ADVISERS, LP	$13.039.744	308.414	0,63%	Ações
CITADEL ADVISORS LLC	$12.251.655	175.500	0,59%	Opção de venda
GREAT POINT PARTNERS LLC	$12.216.750	175.000	0,59%	Ações
Caption Management, LLC	$11.944.491	171.100	0,57%	Opção de compra
MILLENNIUM MANAGEMENT LLC	$11.867.700	170.000	0,57%	Opção de compra
CITADEL ADVISORS LLC	$11.434.878	163.800	0,55%	Opção de compra
AMERIPRISE FINANCIAL INC	$11.050.085	158.288	0,53%	Ações
Quinn Opportunity Partners LLC	$10.686.236	153.076	0,51%	Ações
GOLDMAN SACHS GROUP INC	$10.011.801	143.415	0,48%	Ações
Rhenman & Partners Asset Management AB	$9.860.662	141.250	0,47%	Ações
Qube Research & Technologies Ltd	$9.111.671	130.521	0,44%	Ações
LMR Partners LLP	$9.075.300	130.000	0,44%	Opção de venda
Soleus Capital Management, L.P.	$8.960.951	128.362	0,43%	Ações
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A.	$8.570.364	122.767	0,41%	Ações
Stonepine Capital Management, LLC	$8.422.856	120.654	0,40%	Ações
SummitTX Capital, L.P.	$7.883.923	112.934	0,38%	Ações
APEIRON CAPITAL Ltd	$7.429.948	106.431	0,36%	Ações
CITIGROUP INC	$7.034.824	100.771	0,34%	Ações
ING GROEP NV	$6.981.000	100.000	0,33%	Ações
LMR Partners LLP	$6.981.000	100.000	0,33%	Ações
Susquehanna Portfolio Strategies, LLC	$6.685.704	95.770	0,32%	Ações
Militia Capital Management LLC	$6.282.900	90.000	0,30%	Ações
ACT CAPITAL MANAGEMENT, LLC	$6.234.033	89.300	0,30%	Ações
Tetragon Partners GP Ltd	$6.073.191	86.996	0,29%	Ações
READYSTATE ASSET MANAGEMENT LP	$5.941.529	85.110	0,28%	Ações
Birchview Capital, LP	$5.654.610	81.000	0,27%	Ações
BlackRock, Inc.	$5.444.412	77.989	0,26%	Ações
GROUP ONE TRADING LLC	$4.912.600	70.371	0,24%	Ações
ALGERT GLOBAL LLC	$4.686.345	67.130	0,22%	Ações
Moody Aldrich Partners LLC	$4.477.264	64.135	0,21%	Ações
WOLVERINE TRADING, LLC	$4.330.620	73.500	0,21%	Opção de venda
Swiss National Bank	$4.300.296	61.600	0,21%	Ações
F/m Investments LLC	$4.229.439	60.585	0,20%	Ações
BANK OF AMERICA CORP /DE/	$4.227.764	60.561	0,20%	Ações
ExodusPoint Capital Management, LP	$4.084.374	58.507	0,20%	Ações
Trexquant Investment LP	$3.956.831	56.680	0,19%	Ações
K2 PRINCIPAL FUND, L.P.	$3.522.962	50.465	0,17%	Ações
WOLVERINE TRADING, LLC	$3.403.101	57.758	0,16%	Ações
RHUMBLINE ADVISERS	$3.008.381	43.094	0,14%	Ações
MORGAN STANLEY	$2.943.050	42.158	0,14%	Ações
Voleon Capital Management LP	$2.850.901	40.838	0,14%	Ações
Anson Funds Management LP	$2.829.748	40.535	0,14%	Ações
Atom Investors LP	$2.828.631	40.519	0,14%	Ações
WOLVERINE TRADING, LLC	$2.792.808	47.400	0,13%	Opção de compra
Burkehill Global Management, LP	$2.792.400	40.000	0,13%	Ações
NOMURA HOLDINGS INC	$2.792.400	40.000	0,13%	Opção de venda
IRIDIAN ASSET MANAGEMENT LLC/CT	$2.708.768	38.802	0,13%	Ações
NOMURA HOLDINGS INC	$2.698.645	38.657	0,13%	Ações
Jefferies Financial Group Inc.	$2.664.299	38.165	0,13%	Ações
ALLIANCEBERNSTEIN L.P.	$2.590.200	36.000	0,12%	Ações
Connor, Clark & Lunn Investment Management Ltd.	$2.575.780	36.897	0,12%	Ações
ALPS ADVISORS INC	$2.386.664	34.188	0,11%	Ações
FRED ALGER MANAGEMENT, LLC	$2.350.712	33.673	0,11%	Ações
TUDOR INVESTMENT CORP ET AL	$2.345.616	33.600	0,11%	Opção de compra
Bank of New York Mellon Corp	$2.306.522	33.040	0,11%	Ações
Ghisallo Capital Management LLC	$2.233.920	32.000	0,11%	Ações
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	$2.063.670	28.682	0,10%	Ações
Blackstone Inc.	$2.002.011	28.678	0,10%	Ações
KVP Capital Advisors, LP	$1.877.889	26.900	0,09%	Ações
Ishara Investments LP	$1.860.437	26.650	0,09%	Ações
Erste Asset Management GmbH	$1.830.920	28.000	0,09%	Ações
Caption Management, LLC	$1.822.041	26.100	0,09%	Opção de venda
WINTON GROUP Ltd	$1.808.079	25.900	0,09%	Ações
K2 PRINCIPAL FUND, L.P.	$1.745.250	25.000	0,08%	Opção de compra
Empowered Funds, LLC	$1.636.416	23.441	0,08%	Ações

Executivos da empresa 40 insiders · 20 diretores · 18 conselheiros

Investidor com informação privilegiada	Função	Última atividade	Ações detidas	Vendas 12m	Líquido 12m
Howard W Robin	President & CEO	24 de Julho de 2026 A	55.045	20	$-2.224.055
Jillian B. Thomsen	Chief Financial Officer	16 de Fevereiro de 2023 S	313.497	0	$0
Gil M Labrucherie	SVP, COO & CFO	16 de Maio de 2022 S	312.905	0	$0
Timothy Harkness	SVP & Chief Financial Officer	23 de Agosto de 2007 A	—	0	$0
Louis Drapeau	Sr. VP Finance, CFO	14 de Maio de 2007 A	6.000	0	$0
Milton J Harris	President of Nektar AL	4 de Março de 2004 S	743.904	0	$0
John Nicholson	SVP & Chief Operating Officer	16 de Agosto de 2019 S	162.759	0	$0
Bharat M Chowrira	Chief Operating Officer	1 de Fevereiro de 2010 A	—	0	$0
Jonathan Zalevsky	Chief R&D Officer	24 de Julho de 2026 A	9.756	12	$-1.052.364
Mark Andrew Wilson	Chief Legal Officer	21 de Novembro de 2025 A	21.585	2	$-52.171
John Northcott	SVP & Chief Commercial Officer	16 de Maio de 2022 S	223.210	0	$0
Stephen K Doberstein	SVP & Chief Scientific Officer	5 de Setembro de 2019 P	107.668	0	$0
Maninder Hora	SVP Pharma Dev & Mfg Ops	16 de Maio de 2019 S	94.694	0	$0
Ivan P. Gergel	SVP & Chief Medical Officer	15 de Novembro de 2017 A	56.553	0	$0
Robert Medve	SVP & Chief Medical Officer	5 de Fevereiro de 2014 A	—	0	$0
Rinko Ghosh	Chief Business Officer	6 de Fevereiro de 2013 A	9.753	0	$0
Randall W Moreadith	SVP Drug Development	23 de Fevereiro de 2009 A	—	0	$0
John Stuart Patton	Chief Scientific Officer	14 de Novembro de 2008 M	313.880	0	$0
Nevan C Elam	SVP & Head of Pulmonary Bus	25 de Fevereiro de 2008 A	1.400	0	$0
David Johnston	SVP, Research & Development	14 de Maio de 2007 D	6.600	0	$0
Diana Brainard	Conselheiro	30 de Setembro de 2025 A	28.560	0	$0
Jeffrey Robert Ajer	Conselheiro	30 de Setembro de 2025 A	34.153	0	$0
Robert Chess	Conselheiro	30 de Setembro de 2025 A	255.273	0	$0
Scott R Greer	Conselheiro	30 de Setembro de 2025 A	303.574	0	$0
Roy A Whitfield	Conselheiro	30 de Setembro de 2025 A	216.250	0	$0
Myriam Curet	Conselheiro	19 de Setembro de 2023 A	27.418	0	$0
Karin Eastham	Conselheiro	16 de Setembro de 2022 A	23.233	0	$0
Lutz Lingnau	Conselheiro	22 de Setembro de 2020 A	35.800	0	$0
Christopher A Kuebler	Conselheiro	27 de Setembro de 2018 A	45.250	0	$0
Dennis L Winger	Conselheiro	21 de Agosto de 2018 M	42.750	0	$0
Joseph J Krivulka	Conselheiro	19 de Setembro de 2017 A	82.000	0	$0
Susan Wang	Conselheiro	20 de Novembro de 2015 M	20.000	0	$0
BROWN MICHAEL A/CA	Conselheiro	15 de Setembro de 2009 A	10.000	0	$0
Hoyoung Huh	Conselheiro	2 de Dezembro de 2008 A	—	0	$0
Irwin Lerner	Conselheiro	2 de Dezembro de 2008 A	10.000	0	$0
James B Glavin	Conselheiro	4 de Setembro de 2003 A	—	0	$0
Masuoka K. Lorianne	—	8 de Fevereiro de 2011 A	—	0	$0
Ajit Gill	President & CEO	23 de Março de 2006 S	87.991	0	$0
Ajay Bansal	—	10 de Março de 2006 S	5.166	0	$0
Melvin Perelman	—	2 de Setembro de 2004 A	—	0	$0

Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto

Ativistas e proprietários de 5%+ 1 participação

Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.

Declarante	Declarado	Participação	Status	Propósito	Declaração
Nektar Therapeutics (	22 de Agosto de 2005	—	Declaração inicial	M&A / venda	SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Participação em ETFs Detido por 28 ETFs

O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.

Fundo	Peso	Unidades	Em	Fonte
LFSC · RBB Fund, Inc.	3,14%	50.876 NS	31 de Maio de 2026	N-PORT
SPIT · RBB Fund, Inc.	3,11%	10.455 NS	30 de Abril de 2026	N-PORT
PILL · Direxion Shares ETF Trust	1,55%	2.353 NS	30 de Abril de 2026	N-PORT
BBC · ETFis Series Trust I	1,15%	5.045 NS	30 de Abril de 2026	N-PORT
QQQS · Invesco Exchange-Traded Fund Trust …	0,58%	1.726 SH	8 de Agosto de 2026	Diário
IHE · iShares Trust	0,55%	120.730 SH	8 de Agosto de 2026	Diário
PRFZ · Invesco Exchange-Traded Fund Trust	0,16%	59.612 SH	8 de Agosto de 2026	Diário
IWO · iShares Trust	0,14%	278.376 SH	8 de Agosto de 2026	Diário
VTWG · VANGUARD SCOTTSDALE FUNDS	0,13%	33.135 SH	8 de Agosto de 2026	Diário
TMFX · RBB Fund, Inc.	0,09%	455 NS	31 de Maio de 2026	N-PORT
IWM · iShares Trust	0,08%	877.973 SH	8 de Agosto de 2026	Diário
VTWO · VANGUARD SCOTTSDALE FUNDS	0,07%	198.365 SH	8 de Agosto de 2026	Diário
ISCV · iShares Trust	0,07%	6.414 SH	8 de Agosto de 2026	Diário
SCHA · SCHWAB STRATEGIC TRUST	0,04%	151.830 NS	31 de Maio de 2026	N-PORT
FHLC · FIDELITY COVINGTON TRUST	0,03%	11.131 NS	30 de Abril de 2026	N-PORT
ISCB · iShares Trust	0,03%	1.294 SH	8 de Agosto de 2026	Diário
VXF · VANGUARD INDEX FUNDS	0,03%	387.471 SH	8 de Agosto de 2026	Diário
VHT · VANGUARD WORLD FUND	0,03%	92.340 SH	8 de Agosto de 2026	Diário
WSML · iShares Trust	0,02%	1.887 SH	8 de Agosto de 2026	Diário
VTWV · VANGUARD SCOTTSDALE FUNDS	0,02%	3.096 SH	8 de Agosto de 2026	Diário
IWN · iShares Trust	0,02%	32.466 SH	8 de Agosto de 2026	Diário
ONEQ · Fidelity Commonwealth Trust	0,00%	6.903 NS	31 de Maio de 2026	N-PORT
ITOT · iShares Trust	0,00%	48.124 SH	8 de Agosto de 2026	Diário
IWV · iShares Trust	0,00%	9.139 SH	8 de Agosto de 2026	Diário
TILT · FlexShares Trust	0,00%	770 NS	30 de Abril de 2026	N-PORT
SCHB · SCHWAB STRATEGIC TRUST	0,00%	18.540 NS	31 de Maio de 2026	N-PORT
VTI · VANGUARD INDEX FUNDS	0,00%	1.075.430 SH	8 de Agosto de 2026	Diário
VTHR · VANGUARD SCOTTSDALE FUNDS	0,00%	2.837 SH	8 de Agosto de 2026	Diário

Sobre Nektar Therapeutics - Common Stock Visão geral da empresa da Wikipedia

Background

Pipeline

NKTR Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas

NKTR Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização

Médias móveis e sobreposições

Volume

Osciladores

Momento e tendência

Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS

Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?

Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC

Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial

Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos

Métricas por Ação EPS, valor patrimonial por ação, fluxo de caixa por ação, dividendo por ação

Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber

NKTR Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta

Preço-alvo de 12 meses

Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados

Comparação de pares (subindústria GICS) Métricas chave vs pares do setor

Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa

Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos

Últimas notícias Notícias recentes mencionando esta empresa

Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos

Investidores institucionais (13F) 269 declarantes · $2.1B total · Em 30 de Junho de 2026

Executivos da empresa 40 insiders · 20 diretores · 18 conselheiros

Ativistas e proprietários de 5%+ 1 participação

Participação em ETFs Detido por 28 ETFs